


What is endometrial cancer?

Endometrial cancer is a cancer that originates in the inner lining of the uterus, known as the endometrium.¹



Signs and symptoms¹

Symptoms common in all stages of endometrial cancer:

Abnormal vaginal bleeding is the most common symptom and should be discussed with your doctor. This may include vaginal bleeding or discharge not related to menstruation, or vaginal bleeding after menopause.

Symptoms more common in advanced endometrial cancer:

- Difficult or painful urination
- Pain during sexual intercourse
- Pain in the pelvic area or lower back

Endometrial cancer is the most common gynaecologic cancer in Canada, and the fourth most common cancer among females.^{2,3}

More than 8,000 people are diagnosed with endometrial cancer in Canada each year.⁴

The number of people diagnosed with endometrial cancer is increasing. The incidence rate is estimated to rise by almost 40% globally by 2040, as compared to 2020.⁵

At the time of diagnosis, 15-20% of patients with endometrial cancer will have advanced disease, when the cancer is more difficult to treat.^{6,7}

Most endometrial cancer patients are diagnosed at an early stage, when prognosis is optimal. However, due to the high incidence of endometrial cancer, it has the 3rd highest mortality rate of gynaecologic cancers.⁴

Endometrial cancer is most often diagnosed in people between the ages of 50 and 70 years old.⁸




Biomarker testing

Biomarker and genetic testing are critical to inform treatment plans.

Common biomarker testing includes assessment of mismatch repair (MMR) or microsatellite instability (MSI). Changes in these biomarkers are common in endometrial cancer and may help guide treatment decisions.

Other important biomarkers to test for can include estrogen receptors, progesterone receptors, p53 and HER2.^{9,10}



Treatment

Treatment for endometrial cancer may include a combination of the following:¹¹

- Surgery
- Systemic treatments, such as immunotherapy and chemotherapy, may be considered for those with higher-risk or more advanced disease

1. Endometrial Cancer Treatment (PDQ®)—Patient Version. National Cancer Institute. <https://www.cancer.gov/types/uterine/patient/endometrial-treatment-pdq>. Accessed January 2026.

2. Sobel, M., Simpson, A.N. and Ferguson, S.E. (2021) Endometrial cancer. Canadian Medical Association journal. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8443285>. Accessed August 2026.

3. Government of Canada. (2015). Chapter 4: Cancer incidence in Canada: trends and projections (1983-2032) – Cancer of the body of the uterus - HPCDP: Volume 35, Supplement 1, Spring 2015 - Canada.ca. <https://www.canada.ca/en/public-health/services/reports-publications/health-promotion-chronic-disease-prevention-canada-research-policy-practice/vol-35-no-1-2015/supplement/page-05.html>. Accessed August 2026.

4. Lee, S. (2026). Uterine cancer statistics. Canadian Cancer Society. <https://cancer.ca/en/cancer-information/cancer-types/uterine/statistics>. Accessed August 2026.

5. International Research on Cancer. Global Cancer Observatory. Cancer Tomorrow. <https://gco.iarc.fr/tomorrow/en/dataviz>. Accessed January 2026.

6. CMP: CancerMPact® Patient Metrics Mar-2023. Cerner Enviza. www.cancermpact.com. Accessed January 2026.

7. Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and Management of Endometrial Cancer. Am Fam Physician. 2016;93(6):468-474. Accessed January 2026.

8. Society for Gynaecological Cancer. Uterine Cancer Risk Factors. <https://www.sgo.org/patient-resources/uterine-cancer/uterine-cancer-risk-factors>. Accessed January 2026.

9. FORCE-Facing Our Risk of Cancer Empowered. Endometrial Cancer Biomarker Testing. <https://www.facingourrisk.org/info/risk-management-and-treatment/cancertreatment/by-cancer-type/endometrial/biomarkers-targeted-immunotherapies>. Updated October 2025. Accessed January 2026.

10. Guan J, Xie L, Luo X et al. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification. Published 2018 October. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6304404/#:~:text=2.,=0.016;%20Table%203>. Accessed February 2026.

11. Massive Bio. Endometrial Cancer Treatment Options. <https://massivebio.com/endometrial-cancer-treatment-options-bio>. Updated November 2025. Accessed February 2026.